Chris Chen, PhD

WuXi Biologics (Shanghai) Co., Ltd.
Dr. Chris Chen is the Chief Executive Officer of WuXi Biologics, a Hong Kong-listed and global Contract Research, Development and Manufacturing Organization (CRDMO) service company. Since appointed as CEO in 2011, Dr. Chen has been leading the company onto the steady high growth path. Under Dr. Chen’s leadership, WuXi Biologics has built a world-class open-access integrated biologics discovery, development and manufacturing platform, enabling over 470 global partners ranging from small firms to top 20 global pharmaceutical companies. During Dr. Chen’s tenure, WuXi Biologics has assembled one of the world’s largest biologics teams, with over 10,000 employees located in China, the United States, Ireland, Germany and Singapore, enabling 150 Investigational New Drug (IND) programs and 12 Biologics License Application (BLA) programs per year. WuXi Biologics successfully passed 23 regulatory inspections from multiple administrations (e.g. U.S. FDA, EMA, China NMPA, and Japan PMDA), demonstrating its established premier-quality systems are in compliance with the highest global regulatory standards.

Dr. Chen also spearheads Environmental, Social and Governance (ESG) Committee for WuXi Biologics and under his guidance, WuXi Biologics leads the industry by implementing the world class single-use disposable technology, which significantly reduced consumption of water and energy, and eliminate 100% use of detergents during cGMP production. WuXi Biologics has been awarded as one of the Best ESG companies by Institutional Investor and has been widely recognized by MSCI, DJSI, FTSE Russell and won many other prestigious recognitions. WuXi Biologics is selected into Hang Seng Index as the only biologics company and makes significant contributions in enabling and working with global partners to fight against the pandemic.

Prior to WuXi Biologics, Dr. Chen served as Chief Operating Officer at Celgene Biopharmaceuticals, where he led the successful development of a high-tier, high-quality commercial process for biosimilar etanercept. He previously held leadership positions at Eli Lilly and Merck.

Dr. Chen obtained bachelor’s degrees in chemical engineering and automation from Tsinghua University and his Ph.D. in chemical engineering from the University of Delaware.